CYBN:CC News and Press, CYBIN INC. From 08/31/22

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving for...

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by th...

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (ȁ...

- Clinical milestone marks initiation of first ever novel psilocybin analog to enter clinical development – Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on ...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chie...

Psychedelics have seen a surge in popularity amid significantly increased interest in both the mainstream and scientific communities. Initial studies show that these mind-altering drugs have the potential to alleviate mental health conditions such as post-traumatic disorder , anxiety, eati...

Thanks to increased scientific interest in psychedelics because of their purported mental health benefits , the substances have seen a significant resurgence in mainstream popularity. Reform activists across the country have spent the last couple of years trying to legalize psychedelics a...

Psychedelic research has seen a significant surge in the past few years amid increased interest in psychedelics among the scientific community and the general public. Companies like Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are developing psychedelic-inspired medicines and therapi...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), along with Clinilabs Drug Development Corporation, has been granted a Schedule I license from the U.S. Drug Enforcement Agency (“DEA”) to support...